Evidence map›Paper›PMID 32660183›Full record

ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2020

[Anti-PD-1 therapy in advanced malignant liver tumor-induced type-1 diabetes mellitus: a case report].

T He, X B Zhang, Y X Fei, L Gao, L Gong, Q L Zhang, G Y Chen

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Clinical and immunological characteristics of PD-1 associated fulminant type 1 diabetes mellitus.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

T HeHangzhou Nomal University, Hangzhou 310011, China.
X B ZhangHangzhou Nomal University, Hangzhou 310011, China.
Y X FeiZhejiang University of Traditional Chinese Medicine, Hangzhou 310011, China.
L GaoAffiliated Hospital of Hangzhou Normal University, Hangzhou 310011, China.
L GongAffiliated Hospital of Hangzhou Normal University, Hangzhou 310011, China.
Q L ZhangAffiliated Hospital of Hangzhou Normal University, Hangzhou 310011, China.
G Y ChenAffiliated Hospital of Hangzhou Normal University, Hangzhou 310011, China.
Affiliated Hospital of Hangzhou Normal University · CNZhejiang University · CNZhejiang Chinese Medical University · CN

Funding

Basic Public Welfare Research Project of Zhejiang Province LGC19H20001
6 · The paper itself

Abstract

Immune checkpoint inhibitor (ICI) has been emerged as a major breakthrough in tumor immunotherapy, but its unique mechanism of action has also led to a number of immune-related adverse events (irAE). Type 1 diabetes mellitus (T1DM) is one of the rarest irAEs. This paper reports a case of advanced malignant liver tumor-induced T1DM who received second-line anti-PD-1 therapy and showed initial symptoms of hyperosmolar coma and hyperglycemia. In addition, the relevant literature at home and abroad was collected and reviewed, and the clinical characteristics of T1DM induced by anti-PD-1 therapy were summarized with a view to achieve early detection, diagnosis and treatment.

Indexed as

Diabetes Mellitus, Type 1HyperglycemiaLiver NeoplasmsHumansImmunotherapyProgrammed Cell Death 1 ReceptorProgrammed Cell Death 1 ReceptorImmune checkpoint inhibitorsImmune-related adverse eventsProgrammed death 1Type 1 diabetes mellit

Identifiers

PMID32660183
PMCPMC12769251
OpenAlexW3042559397

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.